Key clinical point: Antiplatelet therapy (APT) reduces the risk for hepatocellular carcinoma (HCC) incidence by 40% and for all-cause mortality by 50% in patients with HCC treated with curative or palliative strategies.

Major finding: APT was associated with a significant reduction in the risk for HCC incidence (odds ratio [OR] 0.63; P < .0001) and post-treatment mortality (OR 0.54; P  =  .006).

Study details: This study was a meta-analysis of 15 studies that investigated the impact of APT on HCC incidence in 2,685,009 individuals and five studies that investigated post-treatment mortality in 3281 patients with HCC, both with respect to APT use.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lai Q et al and the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. Eur J Clin Invest. 2022:e13870 (Sep 8). Doi: 10.1111/eci.13870

Key clinical point: Antiplatelet therapy (APT) reduces the risk for hepatocellular carcinoma (HCC) incidence by 40% and for all-cause mortality by 50% in patients with HCC treated with curative or palliative strategies.

Major finding: APT was associated with a significant reduction in the risk for HCC incidence (odds ratio [OR] 0.63; P < .0001) and post-treatment mortality (OR 0.54; P  =  .006).

Study details: This study was a meta-analysis of 15 studies that investigated the impact of APT on HCC incidence in 2,685,009 individuals and five studies that investigated post-treatment mortality in 3281 patients with HCC, both with respect to APT use.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lai Q et al and the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. Eur J Clin Invest. 2022:e13870 (Sep 8). Doi: 10.1111/eci.13870

Key clinical point: Antiplatelet therapy (APT) reduces the risk for hepatocellular carcinoma (HCC) incidence by 40% and for all-cause mortality by 50% in patients with HCC treated with curative or palliative strategies.

Major finding: APT was associated with a significant reduction in the risk for HCC incidence (odds ratio [OR] 0.63; P < .0001) and post-treatment mortality (OR 0.54; P  =  .006).

Study details: This study was a meta-analysis of 15 studies that investigated the impact of APT on HCC incidence in 2,685,009 individuals and five studies that investigated post-treatment mortality in 3281 patients with HCC, both with respect to APT use.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lai Q et al and the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. Eur J Clin Invest. 2022:e13870 (Sep 8). Doi: 10.1111/eci.13870

Key clinical point: Hepatectomy is beneficial in patients with ≤3 hepatocellular carcinomas (HCC) and no or Child-Pugh (CP) class A cirrhosis, with the long-term results being comparable to those in patients with single HCC.

Major finding: The overall survival was significantly different between patients with Barcelona Clinic Liver Cancer (BCLC) stages A1 and A2 (P  =  .0118), A2 and A3 (P  =  .0013), and B1 and B2 (P  =  .0050) but not between stages A3 and B1 (P  =  .4742). CP class B cirrhosis was an independent prognostic factor for overall survival.

Study details: This single-center retrospective study included 1088 patients who underwent hepatectomy for BCLC stage 0 (n = 88), A (n = 750), or B (n = 250) HCC, with stages A and B categorized into A1 (single nodule 2-5 cm or ≤3 nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (2-3 nodules >3 cm), and B2 (≥4 nodules).

Disclosures: No information on funding source was available. The authors declared no conflicts of interest.

Source: Orimo T et al. Hepatectomy is beneficial in select patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2022 (Sep 13). Doi: 10.1245/s10434-022-12495-z

Key clinical point: Hepatectomy is beneficial in patients with ≤3 hepatocellular carcinomas (HCC) and no or Child-Pugh (CP) class A cirrhosis, with the long-term results being comparable to those in patients with single HCC.

Major finding: The overall survival was significantly different between patients with Barcelona Clinic Liver Cancer (BCLC) stages A1 and A2 (P  =  .0118), A2 and A3 (P  =  .0013), and B1 and B2 (P  =  .0050) but not between stages A3 and B1 (P  =  .4742). CP class B cirrhosis was an independent prognostic factor for overall survival.

Study details: This single-center retrospective study included 1088 patients who underwent hepatectomy for BCLC stage 0 (n = 88), A (n = 750), or B (n = 250) HCC, with stages A and B categorized into A1 (single nodule 2-5 cm or ≤3 nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (2-3 nodules >3 cm), and B2 (≥4 nodules).

Disclosures: No information on funding source was available. The authors declared no conflicts of interest.

Source: Orimo T et al. Hepatectomy is beneficial in select patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2022 (Sep 13). Doi: 10.1245/s10434-022-12495-z

Key clinical point: Hepatectomy is beneficial in patients with ≤3 hepatocellular carcinomas (HCC) and no or Child-Pugh (CP) class A cirrhosis, with the long-term results being comparable to those in patients with single HCC.

Major finding: The overall survival was significantly different between patients with Barcelona Clinic Liver Cancer (BCLC) stages A1 and A2 (P  =  .0118), A2 and A3 (P  =  .0013), and B1 and B2 (P  =  .0050) but not between stages A3 and B1 (P  =  .4742). CP class B cirrhosis was an independent prognostic factor for overall survival.

Study details: This single-center retrospective study included 1088 patients who underwent hepatectomy for BCLC stage 0 (n = 88), A (n = 750), or B (n = 250) HCC, with stages A and B categorized into A1 (single nodule 2-5 cm or ≤3 nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (2-3 nodules >3 cm), and B2 (≥4 nodules).

Disclosures: No information on funding source was available. The authors declared no conflicts of interest.

Source: Orimo T et al. Hepatectomy is beneficial in select patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2022 (Sep 13). Doi: 10.1245/s10434-022-12495-z

Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.

Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.

Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.

Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.

Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183

Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.

Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.

Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.

Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.

Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183

Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.

Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.

Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.

Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.

Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183

Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.

Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.

Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.

Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.

Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024

Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.

Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.

Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.

Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.

Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024

Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.

Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.

Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.

Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.

Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024

Key clinical point: In clinically fit older women with breast cancer (BC), high interleukin-6 (IL-6) and C-reactive protein (CRP) levels before chemotherapy treatment may predict chemotherapy-induced deterioration in frailty status.

Major finding: Overall, 25.8% of patients experienced a decline in frailty status due to chemotherapy. Higher vs lower prechemotherapy levels of both IL-6 and CRP were associated with increased odds of decline in frailty status (odds ratio 3.52; P = .003).

Study details: Findings are from a prospective study, The Hurria Older Patients with BC Study, including 295 robust women with stage I-III BC who received chemotherapy.

Disclosures: This study was supported by the National Institute on Aging and other sources. Three authors declared receiving research funding or royalties, owning patents, or holding stock options in pharmaceutical companies. The other authors declared no conflicts of interest.

Source: Ji J, Sun C-L, et al. Inflammation and clinical decline after adjuvant chemotherapy in older adults with breast cancer: Results from The Hurria Older Patients prospective study. J Clin Oncol. 2022 (Sep 20). Doi: 10.1200/JCO.22.01217

Key clinical point: In clinically fit older women with breast cancer (BC), high interleukin-6 (IL-6) and C-reactive protein (CRP) levels before chemotherapy treatment may predict chemotherapy-induced deterioration in frailty status.

Major finding: Overall, 25.8% of patients experienced a decline in frailty status due to chemotherapy. Higher vs lower prechemotherapy levels of both IL-6 and CRP were associated with increased odds of decline in frailty status (odds ratio 3.52; P = .003).

Study details: Findings are from a prospective study, The Hurria Older Patients with BC Study, including 295 robust women with stage I-III BC who received chemotherapy.

Disclosures: This study was supported by the National Institute on Aging and other sources. Three authors declared receiving research funding or royalties, owning patents, or holding stock options in pharmaceutical companies. The other authors declared no conflicts of interest.

Source: Ji J, Sun C-L, et al. Inflammation and clinical decline after adjuvant chemotherapy in older adults with breast cancer: Results from The Hurria Older Patients prospective study. J Clin Oncol. 2022 (Sep 20). Doi: 10.1200/JCO.22.01217

Key clinical point: In clinically fit older women with breast cancer (BC), high interleukin-6 (IL-6) and C-reactive protein (CRP) levels before chemotherapy treatment may predict chemotherapy-induced deterioration in frailty status.

Major finding: Overall, 25.8% of patients experienced a decline in frailty status due to chemotherapy. Higher vs lower prechemotherapy levels of both IL-6 and CRP were associated with increased odds of decline in frailty status (odds ratio 3.52; P = .003).

Study details: Findings are from a prospective study, The Hurria Older Patients with BC Study, including 295 robust women with stage I-III BC who received chemotherapy.

Disclosures: This study was supported by the National Institute on Aging and other sources. Three authors declared receiving research funding or royalties, owning patents, or holding stock options in pharmaceutical companies. The other authors declared no conflicts of interest.

Source: Ji J, Sun C-L, et al. Inflammation and clinical decline after adjuvant chemotherapy in older adults with breast cancer: Results from The Hurria Older Patients prospective study. J Clin Oncol. 2022 (Sep 20). Doi: 10.1200/JCO.22.01217

Key clinical point: A considerable number of patients with breast cancer (BC) who received sedative-hypnotic medications during adjuvant chemotherapy turned into new, persistent users of those medications even after chemotherapy.

Major finding: Overall, a substantial proportion of benzodiazepine-naive (15.6%)/Z-drug (zolpidem, zaleplon, and eszopiclone, the active stereoisomer of zopiclone)-naive (27.3%) patients who filled ≥1 prescription of benzodiazepine/Z-drug became persistent users. A shorter duration (<4 months) of chemotherapy and receipt of opioid prescriptions during chemotherapy were associated with new persistent sedative-hypnotic use in both benzodiazepine-naive and Z-drug-naive patients (both P ≤ .01).

Study details: Findings are from a study including patients with BC who were naive to benzodiazepine (n = 22,039) or Z-drug (n = 23,816) and received adjuvant chemotherapy.

Disclosures: This work was supported by the Breast Cancer Research Foundation and American Cancer Society. JD Wright declared receiving research support and royalties from some sources.

Source: Cogan JC et al. New and persistent sedative-hypnotic use after adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2022 (Sep 20). Doi: 10.1093/jnci/djac170

Key clinical point: A considerable number of patients with breast cancer (BC) who received sedative-hypnotic medications during adjuvant chemotherapy turned into new, persistent users of those medications even after chemotherapy.

Major finding: Overall, a substantial proportion of benzodiazepine-naive (15.6%)/Z-drug (zolpidem, zaleplon, and eszopiclone, the active stereoisomer of zopiclone)-naive (27.3%) patients who filled ≥1 prescription of benzodiazepine/Z-drug became persistent users. A shorter duration (<4 months) of chemotherapy and receipt of opioid prescriptions during chemotherapy were associated with new persistent sedative-hypnotic use in both benzodiazepine-naive and Z-drug-naive patients (both P ≤ .01).

Study details: Findings are from a study including patients with BC who were naive to benzodiazepine (n = 22,039) or Z-drug (n = 23,816) and received adjuvant chemotherapy.

Disclosures: This work was supported by the Breast Cancer Research Foundation and American Cancer Society. JD Wright declared receiving research support and royalties from some sources.

Source: Cogan JC et al. New and persistent sedative-hypnotic use after adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2022 (Sep 20). Doi: 10.1093/jnci/djac170

Key clinical point: A considerable number of patients with breast cancer (BC) who received sedative-hypnotic medications during adjuvant chemotherapy turned into new, persistent users of those medications even after chemotherapy.

Major finding: Overall, a substantial proportion of benzodiazepine-naive (15.6%)/Z-drug (zolpidem, zaleplon, and eszopiclone, the active stereoisomer of zopiclone)-naive (27.3%) patients who filled ≥1 prescription of benzodiazepine/Z-drug became persistent users. A shorter duration (<4 months) of chemotherapy and receipt of opioid prescriptions during chemotherapy were associated with new persistent sedative-hypnotic use in both benzodiazepine-naive and Z-drug-naive patients (both P ≤ .01).

Study details: Findings are from a study including patients with BC who were naive to benzodiazepine (n = 22,039) or Z-drug (n = 23,816) and received adjuvant chemotherapy.

Disclosures: This work was supported by the Breast Cancer Research Foundation and American Cancer Society. JD Wright declared receiving research support and royalties from some sources.

Source: Cogan JC et al. New and persistent sedative-hypnotic use after adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2022 (Sep 20). Doi: 10.1093/jnci/djac170

Key clinical point: One of the key factors influencing contraceptive use in premenopausal women with early breast cancer (BC) is the use of contraception at the time of diagnosis.

Major finding: At diagnosis, 54.2% of patients reported using contraceptives, mostly hormonal (62.7%); however, the use of contraception decreased significantly to 38.9% and 41.2% at the first and second year, respectively (P < .001). The use of contraception at diagnosis was associated with higher odds of contraceptive use at years 1 (adjusted odds ratio [aOR] 4.02; 95% CI 3.15-5.14) and 2 (aOR 3.12; 95% CI 2.36-4.14) after diagnosis.

Study details: Findings are from an analysis of the prospective, Cancer Toxicity (CANTO) study including 2900 premenopausal women with early BC.

Disclosures: The CANTO study is supported by the Investment for the Future program of the National Research Agency of France. The authors declared serving as advisors, owning stocks, or receiving grants, personal fees, or royalties from several sources.

Source: Lambertini M et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137 (Sep 23). Doi: 10.1001/jamanetworkopen.2022.33137

Key clinical point: One of the key factors influencing contraceptive use in premenopausal women with early breast cancer (BC) is the use of contraception at the time of diagnosis.

Major finding: At diagnosis, 54.2% of patients reported using contraceptives, mostly hormonal (62.7%); however, the use of contraception decreased significantly to 38.9% and 41.2% at the first and second year, respectively (P < .001). The use of contraception at diagnosis was associated with higher odds of contraceptive use at years 1 (adjusted odds ratio [aOR] 4.02; 95% CI 3.15-5.14) and 2 (aOR 3.12; 95% CI 2.36-4.14) after diagnosis.

Study details: Findings are from an analysis of the prospective, Cancer Toxicity (CANTO) study including 2900 premenopausal women with early BC.

Disclosures: The CANTO study is supported by the Investment for the Future program of the National Research Agency of France. The authors declared serving as advisors, owning stocks, or receiving grants, personal fees, or royalties from several sources.

Source: Lambertini M et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137 (Sep 23). Doi: 10.1001/jamanetworkopen.2022.33137

Key clinical point: One of the key factors influencing contraceptive use in premenopausal women with early breast cancer (BC) is the use of contraception at the time of diagnosis.

Major finding: At diagnosis, 54.2% of patients reported using contraceptives, mostly hormonal (62.7%); however, the use of contraception decreased significantly to 38.9% and 41.2% at the first and second year, respectively (P < .001). The use of contraception at diagnosis was associated with higher odds of contraceptive use at years 1 (adjusted odds ratio [aOR] 4.02; 95% CI 3.15-5.14) and 2 (aOR 3.12; 95% CI 2.36-4.14) after diagnosis.

Study details: Findings are from an analysis of the prospective, Cancer Toxicity (CANTO) study including 2900 premenopausal women with early BC.

Disclosures: The CANTO study is supported by the Investment for the Future program of the National Research Agency of France. The authors declared serving as advisors, owning stocks, or receiving grants, personal fees, or royalties from several sources.

Source: Lambertini M et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137 (Sep 23). Doi: 10.1001/jamanetworkopen.2022.33137

Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.

Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.

Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.

Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1

Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.

Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.

Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.

Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1

Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.

Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.

Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.

Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1

Key clinical point: Endocrine therapy (ET) improved survival outcomes in all patients with small pT1a-b, estrogen receptor-positive (ER+) breast cancer (BC), especially in patients with grade 2-3 tumors.

Major finding: No adjuvant ET vs adjuvant ET was associated with decreased disease-free survival (DFS) in the overall cohort of patients with pT1a-bN0 ER+ BC (hazard ratio [HR] 1.275; P = .047) and in those with grade 2-3 tumors (HR 1.502; P = .049); however, ET did not affect DFS outcomes in grade 1 pT1a-bN0 ER+ BC.

Study details: Findings are from a retrospective, observational study including 5545 patients with pT1a-b ER+ BC, of which the majority (80.3%) received adjuvant ET.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Houvenaeghel G et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. Eur J Cancer. 2022;176:58-69 (Oct 1). Doi: 10.1016/j.ejca.2022.08.027

Key clinical point: Endocrine therapy (ET) improved survival outcomes in all patients with small pT1a-b, estrogen receptor-positive (ER+) breast cancer (BC), especially in patients with grade 2-3 tumors.

Major finding: No adjuvant ET vs adjuvant ET was associated with decreased disease-free survival (DFS) in the overall cohort of patients with pT1a-bN0 ER+ BC (hazard ratio [HR] 1.275; P = .047) and in those with grade 2-3 tumors (HR 1.502; P = .049); however, ET did not affect DFS outcomes in grade 1 pT1a-bN0 ER+ BC.

Study details: Findings are from a retrospective, observational study including 5545 patients with pT1a-b ER+ BC, of which the majority (80.3%) received adjuvant ET.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Houvenaeghel G et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. Eur J Cancer. 2022;176:58-69 (Oct 1). Doi: 10.1016/j.ejca.2022.08.027

Key clinical point: Endocrine therapy (ET) improved survival outcomes in all patients with small pT1a-b, estrogen receptor-positive (ER+) breast cancer (BC), especially in patients with grade 2-3 tumors.

Major finding: No adjuvant ET vs adjuvant ET was associated with decreased disease-free survival (DFS) in the overall cohort of patients with pT1a-bN0 ER+ BC (hazard ratio [HR] 1.275; P = .047) and in those with grade 2-3 tumors (HR 1.502; P = .049); however, ET did not affect DFS outcomes in grade 1 pT1a-bN0 ER+ BC.

Study details: Findings are from a retrospective, observational study including 5545 patients with pT1a-b ER+ BC, of which the majority (80.3%) received adjuvant ET.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Houvenaeghel G et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. Eur J Cancer. 2022;176:58-69 (Oct 1). Doi: 10.1016/j.ejca.2022.08.027

Key clinical point: Repeat breast-conserving surgery (re-BCS) worsened survival outcomes in patients with small ipsilateral breast tumor recurrence (IBTR), especially in those with estrogen receptor-negative (ER−) IBTR and those who omitted radiation after re-BCS.

Major finding: Compared with mastectomy, re-BCS was associated with worse overall survival (OS; hazard ratio [HR] 1.342; 95% CI 1.084-1.663) and breast cancer-specific survival (BCSS; HR 1.454; 95% CI 1.004-2.105). After re-BCS, the omission of radiation worsened OS (overall re-BCS without radiation: HR 1.384; 95% CI 1.110-1.724; and negative IBTR ER re-BCS without radiation: HR 1.972; 95% CI 1.191-3.265, respectively) and BCSS (overall re-BCS without radiation: HR 1.577; 95% CI 1.075-2.314; and negative IBTR ER re-BCS without radiation: HR 2.097; 95% CI 1.053-4.178, respectively).

Study details: Findings are from a population-based cohort study including 3648 patients with small IBTR, of which 22.4% of patients underwent re-BCS and the remaining patients underwent mastectomy.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Li Y et al. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence? Cancer. 2022 (Sep 20). Doi: 10.1002/cncr.34468

Key clinical point: Repeat breast-conserving surgery (re-BCS) worsened survival outcomes in patients with small ipsilateral breast tumor recurrence (IBTR), especially in those with estrogen receptor-negative (ER−) IBTR and those who omitted radiation after re-BCS.

Major finding: Compared with mastectomy, re-BCS was associated with worse overall survival (OS; hazard ratio [HR] 1.342; 95% CI 1.084-1.663) and breast cancer-specific survival (BCSS; HR 1.454; 95% CI 1.004-2.105). After re-BCS, the omission of radiation worsened OS (overall re-BCS without radiation: HR 1.384; 95% CI 1.110-1.724; and negative IBTR ER re-BCS without radiation: HR 1.972; 95% CI 1.191-3.265, respectively) and BCSS (overall re-BCS without radiation: HR 1.577; 95% CI 1.075-2.314; and negative IBTR ER re-BCS without radiation: HR 2.097; 95% CI 1.053-4.178, respectively).

Study details: Findings are from a population-based cohort study including 3648 patients with small IBTR, of which 22.4% of patients underwent re-BCS and the remaining patients underwent mastectomy.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Li Y et al. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence? Cancer. 2022 (Sep 20). Doi: 10.1002/cncr.34468

Key clinical point: Repeat breast-conserving surgery (re-BCS) worsened survival outcomes in patients with small ipsilateral breast tumor recurrence (IBTR), especially in those with estrogen receptor-negative (ER−) IBTR and those who omitted radiation after re-BCS.

Major finding: Compared with mastectomy, re-BCS was associated with worse overall survival (OS; hazard ratio [HR] 1.342; 95% CI 1.084-1.663) and breast cancer-specific survival (BCSS; HR 1.454; 95% CI 1.004-2.105). After re-BCS, the omission of radiation worsened OS (overall re-BCS without radiation: HR 1.384; 95% CI 1.110-1.724; and negative IBTR ER re-BCS without radiation: HR 1.972; 95% CI 1.191-3.265, respectively) and BCSS (overall re-BCS without radiation: HR 1.577; 95% CI 1.075-2.314; and negative IBTR ER re-BCS without radiation: HR 2.097; 95% CI 1.053-4.178, respectively).

Study details: Findings are from a population-based cohort study including 3648 patients with small IBTR, of which 22.4% of patients underwent re-BCS and the remaining patients underwent mastectomy.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Li Y et al. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence? Cancer. 2022 (Sep 20). Doi: 10.1002/cncr.34468